Invizius Company
Invizius offers extra-corporeal treatments for patients that includes dialysis, cardiopulmonary bypass, and ECMO involve the circulation of the patient's blood supply through a machine. Invizius develops H-Guard, an advanced hemocompatible coating capable of preventing foreign body reactions in the blood at the source. Invizius aims to revolutionize dialysis and other extracorporeal treatments.
Founded Date:
2017
Investor Type:
N/A
Employee Number:
Undisclosed
Investment Stage:
N/A
Funding Status:
Seed
Number Of Exists:
N/A
Technology:
Other
Industry:
Preventive Medicine
Headquarters:
Edinburgh, Edinburgh, City of, United Kingdom